|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng H, Zheng R, Zhang S, Zuo T, Xia C,
Zou X and Chen W: Esophageal cancer statistics in China, 2011:
Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang W, Li H, Chen X, Su M, Lin R and Zou
C: Phase II study of concurrent chemoradiotherapy with a modified
target volumes delineation method for inoperable oesophagealcancer
patients. Br J Radiol. 90:201703282017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lagergren J, Smyth E, Cunningham D and
Lagergren P: Oesophageal cancer. Lancet. 390:2383–2396. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cress WD, Yu P and Wu J: Expression and
alternative splicing of the cyclin-dependent kinase inhibitor-3
gene in human cancer. Int J Biochem Cell Biol. 91:98–101. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu D, Zhang J, Wu Y, Shi G, Yuan H, Lu Z,
Zhu Q, Wu P, Lu C, Guo F, et al: YY1 suppresses proliferation and
migration of pancreatic ductal adenocarcinoma by regulating the
CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 142:1392–1404.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu C, Cao H, He X, Sun P, Feng Y, Chen L
and Gong H: Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a
critical role in prostate cancer via regulating cell cycle and DNA
replication signaling. Biomed Pharmacother. 96:1109–1118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nalepa G, Barnholtz-Sloan J, Enzor R, Dey
D, He Y, Gehlhausen JR, Lehmann AS, Park SJ, Yang Y, Yang X, et al:
The tumor suppressor CDKN3 controls mitosis. J Cell Biol.
201:997–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song H, Hanlon N, Brown NR, Noble ME,
Johnson LN and Barford D: Phosphoprotein-protein interactions
revealed by the crystal structure of kinase-associated phosphatase
in complex with phosphoCDK2. Mol Cell. 7:615–626. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yeh CT, Lu SC, Chao CH and Chao ML:
Abolishment of the interaction between cyclin-dependent kinase 2
and Cdk-associated protein phosphatase by a truncated KAP mutant.
Biochem Biophys Res Commun. 305:311–314. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Sun L, Huang J and Jiang M:
Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle
computational network between human non-malignancy associated
hepatitis/cirrhosis and hepatocellular carcinoma (HCC)
transformation. Cell Prolif. 44:291–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barrón EV, Roman-Bassaure E,
Sánchez-Sandoval AL, Espinosa AM, Guardado-Estrada M, Medina I,
Juárez E, Alfaro A, Bermúdez M, Zamora R, et al: CDKN3 mRNA as a
biomarker for survival and therapeutic target in cervical cancer.
PLoS One. 10:e01373972015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zang X, Chen M, Zhou Y, Xiao G, Xie Y and
Wang X: Identifying CDKN3 gene expression as a prognostic biomarker
in lung adenocarcinoma via meta-analysis. Cancer Inform. 14 (Suppl
2):S183–S191. 2015.
|
|
17
|
Wang H, Chen H, Zhou H, Yu W and Lu Z:
Cyclin-dependent kinase inhibitor 3 promotes cancer cell
proliferation and tumorigenesis in nasopharyngeal carcinoma by
targeting p27. Oncol Res. 25:1431–1440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng M, Wang J, Chen Y, Zhang L, Xie G,
Liu Q, Zhang T, Yuan P and Liu D: Silencing cyclin-dependent kinase
inhibitor 3 inhibits the migration of breast cancer cell lines. Mol
Med Rep. 14:1523–1530. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu CQ, Zhu ST, Wang M, Guo SL, Sun XJ,
Cheng R, Xing J, Wang WH, Shao LL and Zhang ST: Pathway analysis of
differentially expressed genes in human esophageal squamous cell
carcinoma. Eur Rev Med Pharmacol Sci. 19:1652–1661. 2015.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu N, Clifford RJ, Yang HH, Wang C,
Goldstein AM, Ding T, Taylor PR and Lee MP: Genome wide analysis of
DNA copy number neutral loss of heterozygosity (CNNLOH) and its
relation to gene expression in esophageal squamous cell carcinoma.
BMC Genomics. 11:5762010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen YK, Tung CW, Lee JY, Hung YC, Lee CH,
Chou SH, Lin HS, Wu MT and Wu IC: Plasma matrix metalloproteinase 1
improves the detection and survival prediction of esophageal
squamous cell carcinoma. Sci Rep. 6:300572016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lai MW, Chen TC, Pang ST and Yeh CT:
Overexpression of cyclin-dependent kinase-associated protein
phosphatase enhances cell proliferation in renal cancer cells. Urol
Oncol. 30:871–878. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang SL, Chen TJ, Lee YE, Lee SW, Lin LC
and He HL: CDKN3 expression is an independent prognostic factor and
associated with advanced tumor stage in nasopharyngeal carcinoma.
Int J Med Sci. 15:992–998. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Ji S, Fu LY, Jiang T, Wu D and Meng
FD: Knockdown of Cyclin-dependent kinase inhibitor 3 inhibits
proliferation and invasion in human gastric cancer cells. Oncol
Res. 25:721–731. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dai W, Miao H, Fang S, Fang T, Chen N and
Li M: CDKN3 expression is negatively associated with pathological
tumor stage and CDKN3 inhibition promotes cell survival in
hepatocellular carcinoma. Mol Med Rep. 14:1509–1514. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang J, Che W, Wang W, Su G, Zhen T and
Jiang Z: CDKN3 promotes tumor progression and confers cisplatin
resistance via RAD51 in esophageal cancer. Cancer Manag Res.
11:3253–3264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J, Min L, Zhu S, Guo Q, Li H, Zhang Z,
Zhao Y, Xu C and Zhang S: Cyclin-dependent kinase inhibitor 3
promoted cell proliferation by driving cell cycle from G1 to S
phase in esophageal squamous cell carcinoma. J Cancer.
10:1915–1922. 2019. View Article : Google Scholar : PubMed/NCBI
|
